The TRIH Grant supports:
- research with strong commercial potential, likely to attract follow-on funding at the conclusion of the grant.
- studies that will facilitate and enable the progression of promising basic research towards testing in clinical trials.
The TRIH Grant does not support basic research into the causes and underpinning biology of hearing loss and tinnitus or the development of devices or software.
TRIH Grant 2019
- Duration: up to three years
- Eligibility: applicants may be from any country and may be from academic institutions and small/medium enterprises (SMEs)
- Value *: Up to £100,000 per year
- expression of interest: 3 May 2019 (5pm GMT)
- full application (by invitation only): 13 June 2019 (5pm GMT)
- funding decisions: November/ December 2019
* Please note that as a charity, it is our policy not to fund any indirect costs or the salaries of permanent employees.
First, an expression of interest must be submitted using the form below. This gives us enough information about the proposed project to understand how well it aligns with the requirements and eligibility of the TRIH scheme.
Applicants whose proposals meet the criteria of the scheme are then invited to submit a full application.
Stages of the application procedure
1. Expression of interest
Expressions of interest are open entry.
Additional information may be requested in order to determine whether an application meets the scheme's criteria.
3. Full application
Full applications are made by invitation only, if your expression of interest is successful.
4. External assessment
All full applications are sent to two or three external referees. These referees rate the scientific value, feasibility and translational potential of each project. Applicants can then respond to the reviewer's feedback if they wish.
5. TRIH Funding Review Panel assessment
The panel considers the full applications and expert reviews, assessing scientific approach and commercial and/or translational potential.
Projects are ranked competitively and funding is awarded to the top-rated projects.
How to apply
Use the form below to submit your expression of interest.
Applicants whose proposals meet the scheme's criteria will be invited to submit a full application. See the document below for full details.
Requirements and eligibility
The scope of the Translational Research Initiative for Hearing call varies from year to year. This year, applications can include:
Small molecule, gene or cell-based approaches for the treatment of hearing loss or tinnitus
Applications can include:
- studies which will enable lead optimisation and/or candidate selection
- pharmacokinetics/Pharmacodynamics (PKPD) studies
- safety/toxicology studies
- drug repositioning/repurposing (applications must contain preliminary data supporting the proposed approach)
- validation of therapeutic targets for the treatment of hearing loss or tinnitus (applications must contain preliminary data supporting the proposed approach)
- studies to strengthen confidence that a target or therapeutic approach will be applicable to human hearing loss or tinnitus
- identification/validation of methods or outcomes that could be used for one or more of the following*:
- patient selection/stratification for clinical trials
- robust measurement of treatment responses in clinical trials.
*Please note that these studies must support the development of a specific therapeutic. General research into outcome measures not aligned to a specific therapeutic should be submitted to other grant schemes of Action on Hearing Loss (i.e Discovery Research Grant Scheme) and Fondation Pour l'Audition.
Areas in which applications will NOT be accepted
This year, applications will not be accepted in the following areas:
- basic research into the causes and underpinning biology of hearing loss and tinnitus
- the development of devices or software
- the optimisation of current clinical protocols
- health service studies.
All applications are sent to two/three external referees in the field who are asked to rate the scientific value, feasibility, and translational potential of the project. The applications and associated peer reviews are then assessed and rated by members of our TRIH funding review panel. The top-rated applications are then put forward for funding.
We decide who to fund based on scientific merit, feasibility, the TRIH Grant eligibility criteria above, and relevance to our Biomedical Research Strategy. Everyone involved in the review process of any grant application is asked to abide by our Code of Conduct and to sign a reviewer agreement with confidentiality clauses.
Applicants are notified of the outcome as soon as possible following the final decision. Feedback is provided to all applicants.
TRIH Funding Review Panel
- Dr Rick Cousins (Independent Drug Discovery & Medicinal Chemistry Advisor)
- Dr Paul England (IOTA Pharmaceuticals Ltd)
- Dr Judith Langfield (Patient representative)
- Dr. Elisa Petris (Syncona)
- Dr. Louise Jones (UKRI MRC)
- Professor Marcelo Rivolta (University of Sheffield)
- Members of the Scientific Committee of Fondation Pour l’Audition.
Additional panel members may be recruited.
Project management and reporting
Successful TRIH grants require annual scientific and financial reporting. This ensures that the milestones are met and the project is successfully completed.
Europe PubMed Central (Europe PMC) and open access publications
Action on Hearing Loss is a member of the Europe PMC Funders' Group. We support open access publications and require Action on Hearing Loss grant holders to make their publications open access.
For more information
Please get in touch if you would like more information about the TRIH grant.
Telephone: +44 (0)20 32276020
Current TRIH projects
- Developing new medicines to treat age-related and noise-induced hearing loss
- Paving the way for new tinnitus treatments
- Identifying aminoglycoside antibiotics that are less toxic to the ear
- Magnetically directing therapy into the inner ear
- Delivery of drugs through the eardrum to treat middle ear infections
- Testing potential drugs to protect the inner ear from ototoxic aminoglycoside antibiotics